RVMD: Retail Attention Spikes as Options Hedging Builds Before November 5

Three distinct signals converged on Revolution Medicines this week. Retail attention has surged to its highest in months. Options traders are buying more protection. Short sellers have added to positions already at a 30-day high.

Retail Crowd Arrives

The clearest new development is a surge in public attention. Wikipedia views and ORTEX page traffic combined to push a retail attention reading 4.7 standard deviations above its own 90-day history as of October 19. That is the kind of spike that typically follows a news event landing on a stock that most generalist investors had not been watching. The company sits 16 days from its November 5 earnings date, where analysts expect results from the commercial launch of Rasonque, its FDA-approved RAS inhibitor for metastatic pancreatic cancer.

Options Market Shifts Toward Hedging

The put-call ratio moved to 0.97 on October 19, 2.3 standard deviations above its 20-day mean of 0.85. The ratio has been range-bound for weeks, so the single-session jump stands out. The 52-week high is 1.80, so absolute positioning is not extreme, but the direction of the move is consistent with fresh hedging demand rather than a change in underlying conviction. The November 5 date gives options activity a clear anchor.

Short Interest Holds at 30-Day High

Short interest has held near the levels established in the October 7 to 9 step-change covered in the prior note. It now sits at 6.1% of the free float, with the one-week change of just under 2% confirming that bears are not retreating. Cost to borrow has pulled back from the 0.63% peak seen mid-week to 0.48%. Availability remains extremely loose at 2,525% of short interest, meaning the lending pool is far from constrained. There are roughly 25 shares available to borrow for every one currently lent out. Short sellers face no mechanical friction.

Corroborating Context

The analyst community has not shifted position. Truist Securities raised its target to $241, RBC Capital moved to $260, and Needham held at $275, all within the past week. The consensus mean target stands at $257.84, against a current close of $182.15. William Blair initiated with an Outperform on October 16. Institutional holders have been adding. BlackRock increased by 2.5 million shares in the quarter to September 30. Capital Research built a new position of over 4 million shares in the same period.

The analyst recommendation score sits at the 99th percentile versus the broader market, according to ORTEX factor data, while the 30-day EPS momentum rank sits at the 14th percentile, a divergence that reflects how early the commercial story is.

The ORTEX short score stands at 46.9, up from 42.3 two weeks ago. That move has continued a steady grind rather than accelerating sharply.

Data Summary

• SI % of free float: 6.1% (30-day high, +23% over one month)
• Cost to borrow: 0.48% (falling; 52-week range low, borrow remains cheap)
• Availability: 2,525% of short interest (extremely loose)
• Put-call ratio: 0.97, z-score 2.3 vs 20-day mean
• Retail attention z-score: 4.7 vs own 90-day history
• Analyst mean target: $257.84 vs close of $182.15
• Next earnings: November 5